Liang Peng, Qiang Zhao, Qibin Li, Miaoxin Li, Caixia Li, Tingting Xu, Xiangyi Jing, Xiang Zhu, Ye Wang, Fucheng Li, Ruihong Liu, Cheng Zhong, Qihao Pan, Binghui Zeng, Qijun Liao, Bin Hu, Zhao‐xia Hu, Yang‐su Huang, Pak Sham, Jinsong Liu, Shuhua Xu, Jun Wang, Zhi‐liang Gao, Yiming Wang – 21 November 2014 – In the past 50 years there have been considerable efforts to identify the cellular receptor of hepatitis B virus (HBV).

Adrian M. Bisceglie, Anna S. Lok, Paul Martin, Norah Terrault, Robert P. Perrillo, Jay H. Hoofnagle – 21 November 2014 – Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti‐CD20 agents ofatumumab or rituximab.

Liang Peng, Qiang Zhao, Qibin Li, Miaoxin Li, Caixia Li, Tingting Xu, Xiangyi Jing, Xiang Zhu, Ye Wang, Fucheng Li, Ruihong Liu, Cheng Zhong, Qihao Pan, Binghui Zeng, Qijun Liao, Bin Hu, Zhao‐xia Hu, Yang‐su Huang, Pak Sham, Jinsong Liu, Shuhua Xu, Jun Wang, Zhi‐liang Gao, Yiming Wang – 21 November 2014 – In the past 50 years there have been considerable efforts to identify the cellular receptor of hepatitis B virus (HBV).

Cédric Langhi, Ángel Baldán – 21 November 2014 – The cell death‐inducing DNA fragmentation factor alpha‐like effector c (CIDEC; also known in rodents as FSP27 or fat‐specific protein 27) is a lipid droplet‐associated protein that promotes intracellular triglyceride (TAG) storage. CIDEC/Fsp27 is highly expressed in adipose tissue, but undetectable in normal liver. However, its hepatic expression rises during fasting or under genetic or diet‐induced hepatosteatosis in both mice and patients.

Jürgen J. Wenzel, Wolfgang Jilg – 21 November 2014

Scott Powers – 21 November 2014

Laurent Chatel‐Chaix, Ralf Bartenschlager – 21 November 2014

Stephen N. Greenhalgh, Kylie P. Conroy, Neil C. Henderson – 21 November 2014 – Rapid evolution in transgenic (Tg) mouse technology now permits cell‐specific and temporal control of fluorescent cell‐labeling and gene inactivation. Here, we discuss the principal strategies that have been utilized to target, label, and manipulate hepatic nonparenchymal cells, with emphasis on the utility of constitutive and inducible Cre‐lox systems.

Yi‐Chun Hung, Chih‐Lin Lin, Chun‐Jen Liu, Hung Hung, Shi‐Ming Lin, Shou‐Dong Lee, Pei‐Jer Chen, Shu‐Chun Chuang, Ming‐Whei Yu – 21 November 2014 – The age and risk level that warrants hepatocellular carcinoma (HCC) screening remains to be defined. To develop risk scores for stratifying average‐risk population for mass HCC screening, we conducted a pooled analysis using data from three cohorts involving 12,377 Taiwanese adults 20‐80 years of age. During 191,240.3 person‐years of follow‐up, 387 HCCs occurred.

Fabrizio Panaro, Boris Guiu, Francis Navarro – 19 November 2014